Yungjin Pharmaceutical Co., Ltd. (003520) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Yungjin Pharmaceutical Co., Ltd. (003520:KRX), powered by AI.

Current Price
₩1,271
P/E Ratio
-1021.1
Market Cap
232.5B
Sector
Healthcare
What is the Yungjin Pharmaceutical Co., Ltd. stock price forecast?

Yungjin Pharmaceutical Co., Ltd. is currently trading at ₩1,271. View real-time AI analysis on Alpha Lenz.

What is Yungjin Pharmaceutical Co., Ltd. insider trading activity?

View the latest insider trading data for Yungjin Pharmaceutical Co., Ltd. on Alpha Lenz.

What is Yungjin Pharmaceutical Co., Ltd.'s P/E ratio?

Yungjin Pharmaceutical Co., Ltd.'s P/E ratio is -1021.1.

Yungjin Pharmaceutical Co., Ltd.

KRX · 003520
₩1,271+6(+0.47%)Market closedKRX regular session 09:00–15:30 KST
Ask about Yungjin Pharmaceutical Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Yungjin Pharmaceutical Co., Ltd. trades at a P/E of -1021.1 (undervalued) with modest ROE of -0.3%.

Ask for details

Company Overview

Yungjin Pharmaceutical Co., Ltd. is a distinguished name in the pharmaceutical industry, primarily engaged in the research, development, and production of pharmaceutical products. The company focuses on delivering a wide array of medicinal solutions, including prescription drugs, over-the-counter medications, and health supplements. Its innovative approach in pharmaceutical formulations caters to various medical needs, encompassing fields such as cardiology, oncology, and infectious diseases. Yungjin Pharmaceutical Co., Ltd. plays a crucial role in the health sector by advancing medical technologies and improving patient care through quality and efficient medication. With a commitment to research and development, the company is pivotal in introducing cutting-edge therapeutic solutions, aiding healthcare practitioners and enhancing patient outcomes globally. The company’s contributions are significant in addressing public health challenges and promoting general wellness in the communities it serves.

CEO이기수
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees574

Company Statistics

FY 2025

Profile

₩232,456,661,101Market Cap
₩254,255,894,050Revenue
182.89MShares Out
574Employees

Margins

30.35%Gross
4.99%EBITDA
1.90%Operating
-0.08%Pre-Tax
-0.09%Net

Valuation

-1021.07P/E
2.54P/B
0.91EV/Sales
23.50EV/EBITDA
-995.39P/FCF

Growth (CAGR)

5.20%Rev 3Yr
4.05%Rev 5Yr
N/AOp Inc 3Yr
66.09%Op Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-0.09%ROA
-0.25%ROE
1.60%ROIC

Financial Health

₩28,426,668,840Cash & Cash Equivalents
₩142,498,582,730Net Debt
186.89%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Yungjin Pharmaceutical Co., Ltd. (ticker: 003520) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 574 employees. Market cap is $232.5B.

The current price is ₩1,271 with a P/E ratio of -1,021.07x and P/B of 2.54x.

ROE is -0.25% and operating margin is 1.90%. Annual revenue is $254.3B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Yungjin Pharmaceutical Co., Ltd. (003520) Stock Forecast 2026 ₩1,271 — Price, Financials & Analyst Targets | Alpha Lenz